pancreatitis: correlation between the severity of the disease and the antienterobacterial common antigen antibody titre. Gut 1984;25:1065-70. 4 Azoles that are active against mycoses are an important advance in the management of serious fungal infections. Recent reports of clinical resistance and failure associated with triazole therapy have been of considerable concern [1] [2] [3] [4] [5] [6] [7] [8] . Candida albicans isolates with high-level resistance to azoles (including fluconazole) have been identified, particularly in patients with advanced HIV infection; detection of these isolates usually occurs after administration of long-term systemic azole regimens, which often include low doses of maintenance fluconazole therapy [1-3, 6, 7]. To date, fluconazole-resistant c. albicans is rare in persons who are not infected with HIV, and reports of nosocomial infection caused by resistant C. albicans are infrequent [4, 5] . Resistance to fluconazole has not been reported in immunocompetent individuals who were not hospitalized. We describe a healthy female who had azoleresistant c. albicans vaginitis that responded to therapy with boric acid.
Symptomatic Vulvovaginitis Due to Fluconazole-Resistant Candida albicans in a Female Who Was Not Infected with Human Immunodeficiency Virus
Azoles that are active against mycoses are an important advance in the management of serious fungal infections. Recent reports of clinical resistance and failure associated with triazole therapy have been of considerable concern [1] [2] [3] [4] [5] [6] [7] [8] . Candida albicans isolates with high-level resistance to azoles (including fluconazole) have been identified, particularly in patients with advanced HIV infection; detection of these isolates usually occurs after administration of long-term systemic azole regimens, which often include low doses of maintenance fluconazole therapy [1-3, 6, 7] . To date, fluconazole-resistant c. albicans is rare in persons who are not infected with HIV, and reports of nosocomial infection caused by resistant C. albicans are infrequent [4, 5] . Resistance to fluconazole has not been reported in immunocompetent individuals who were not hospitalized. We describe a healthy female who had azoleresistant c. albicans vaginitis that responded to therapy with boric acid.
A 38-year-old female with a 3-month history of continuous yeast vaginal infection was referred to the Vaginitis Clinic at Wayne State University (Detroit) on 3 March 1995. Before the referral, the patient had experienced only occasional episodes of candidal vaginitis. Symptoms at presentation included pruritus, vulvovaginal burning, and dyspareunia. During the 3 months before presentation, the patient had received over-the-counter topical antimycotic agents as well as prescribed terconazole and fluconazole (150 mg orally daily) for 1 month.
A pelvic examination revealed erythema and edema of the vulva and vagina, with extensive vulvar excoriation. Examination of the cervix and a bimanual pelvic examination did not reveal any abnormalities. The vaginal pH was 4.3, and a test for amine was negative. Microscopic examination of vaginal secretions in saline revealed no increase in polymorphonuclear neutrophils, no clue cells, and no trichomonads; however, numerous yeast blastospores as well as pseudohyphae were seen. On the assumption that the patient had azole-susceptible C. albicans vulvovaginitis, she was initially treated with fluconazole (150 mg administered every 4th day; three doses total). Culture of vaginal specimens yielded C. albicans.
The patient returned to the clinic 2 weeks later, at which time her condition was only marginally improved (she still had signs of vulvovaginitis); microscopic examination of vaginal secretions in 10% KOH revealed yeast, and culture of a vaginal specimen again yielded C. albicans. While susceptibility tests were being performed, she was treated with clotrimazole vaginal suppositories (100 mg daily for 7 days).
The patient returned to the clinic 10 days later, at which time she was still uncomfortable and had persistent clinical signs of vulvovaginitis; microscopic examination of vaginal secretions in 10% KOH again revealed yeast, and culture of a vaginal specimen again yielded C. albicans. There was no question oflack of compliance with her medications. The patient received therapy with boric acid (600-mg vaginal capsule twice daily for 2 weeks). She returned to the clinic after 17 days; at that time she was asymptomatic and a pelvic examination did not reveal any abnormalities. The results of all laboratory studies (including cultures) were negative, and follow-up examination 6 weeks later revealed that she was clinically and mycologically cured.
In vitro susceptibility tests performed according to NCCLS (National Committee for Clinical Laboratory Standards) methodology [9] revealed that the vaginal C. albicans isolates were susceptible to amphotericin B (MIC, 0.01 j.lg/mL), miconazole (MIC, 0.05 j.lg/mL), and flucytosine (MIC, 0.63 j.lg/mL) and that they were resistant to fluconazole (MIC, > 40 j.lg/mL), itraconazole (MIC, 6.25 j.tg/mL), and ketoconazole (MIC, 3.12 j.lg/mL). The C. albicans isolates had intermediate susceptibility to clotrimazole (MIC, 0.39 j.lg/mL). All three isolates were compared with use of CHEF (contour-clamped homogeneous electric field) typing (data not shown) and found to be an identical C. albicans clone.
To our knowledge, azole-resistant C. albicans has not been previously reported as a cause of vulvovaginitis. We recently reported the results of susceptibility testing of over 500 vaginal yeast isolates, including 300 isolates of C. albicans, obtained from patients in our clinic; no evidence of azole resistance was observed [10] . Our patient's case demonstrated high-level resistance to fluconazole as well as cross-resistance to ketoconazole and itraconazole, drugs that she had not received. She had received a prolonged course of daily fluconazole for 1 month.
We believe that our case is an example of fluconazole resistance that was associated with the development of cross-resistance to other azoles in a vaginal strain of C. albicans in an immunocompetent patient who was not exposed sexually or otherwise to a reservoir that might have selected for resistance in C. albicans. Unfortunately, the specimen of C. albicans isolated before the course of fluconazole was administered was not available to determine preexposure susceptibility; thus, it is unclear at which stage resistance to fluconazole developed. Since superinfection with a resistant isolate is unlikely, it is possible that our patient was initially infected with a fluconazole-resistant strain or that resistance developed during topical azole therapy or under the selective pressure The most important advent in the treatment of streptococcal pharyngitis and the prevention of primary and secondary rheumatic fever as well as the control of these diseases has been the development of intramuscular penicillin G benzathine (PGB), which became available in the United States in 1952. A single intramuscular injection of PGB (with the dosage adjusted according to weight) produces serum levels of penicillin G that are relatively low but that are inhibitory for essentially all strains of group A ,B-hemolytic streptococci (GABHS) for up to 4 weeks [l] . Because of these advantages and since compliance was assured, intramuscular PGB evolved as the "gold standard" for the treatment of streptococcal pharyngitis and the agent of choice for controlling outbreaks of streptococcal infection and preventing primary rheumatic fever in basic trainees in the military [2] .
It is surprising that there have been no reports of studies of serum penicillin levels in highly active basic trainees in the military who received the standard 1.2 million units of intramuscular PGB at the beginning of their training; PGB has been used to control streptococcal infection in these populations of young adults with great success since the mid-1950s [2] . This study was undertaken to provide this information.
